Afamitresgene autoleucel
PreclinicalCell therapy
RocheAfamitresgene autoleucel is one of 18 therapeutic programs targeting Synovial Sarcoma. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
27 competitors in Synovial Sarcoma
#DrugCompanyPhaseTrials
1DTIC-Dome
BayerApproved
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Yondelis
AApotex Inc.
Phase 3
Yervoy
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Iressa
AstraZenecaPhase 2
Herceptin
OOrganon and Co
Phase 2
Fludara
SanofiPhase 1
Gemzar
Johnson & JohnsonPhase 1
Cyramza
Eli LillyPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Afamitresgene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy
- Highest Phase
- Preclinical
- Company